Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma

Next Previous
Trial Profile

Compassionate Use Study of Carfilzomib for Patients With Relapsing or Resistant Multiple Myeloma

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 28 Oct 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 23 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 23 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
  • 23 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top